Uncategorized

Gene editing developer Scribe plots an IPO

Published

on

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version